4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butanethioamide | 722549-49-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butanethioamide
• CAS: 722549-49-7
• 化学式: C₁₂H₁₇N₃S
• 分子量: 235.353
• InChiKey: XOZHSCOGISNQBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  83
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butanethioamide 在 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 3-(4-methylphenyl)-4-{2-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,3-thiazol-4-yl}butanoic acid
  参考文献：
  名称：

  Synthesis of 2,5-thiazole butanoic acids as potent and selective αvβ3 integrin receptor antagonists with improved oral pharmacokinetic properties

  摘要：

  We describe a series of 2,5 thiazole containing compounds, which are potent antagonists of the integrin alpha(V)beta(3) and show selectivity relative to the other integrins, such as alpha(IIB)beta(3) and alpha(V)beta(6). These analogs were demonstrated to have high bioavailability relative to other relative heterocyclic analogs. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.017
• 作为产物：
  描述：

  5-酮基已腈 在 palladium on activated charcoal 吡啶 、 硫化氢 、 氢气 、 三乙胺 、 L-脯氨酸 作用下， 以 乙醇 为溶剂， 生成 4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butanethioamide
  参考文献：
  名称：

  Synthesis of 2,5-thiazole butanoic acids as potent and selective αvβ3 integrin receptor antagonists with improved oral pharmacokinetic properties

  摘要：

  We describe a series of 2,5 thiazole containing compounds, which are potent antagonists of the integrin alpha(V)beta(3) and show selectivity relative to the other integrins, such as alpha(IIB)beta(3) and alpha(V)beta(6). These analogs were demonstrated to have high bioavailability relative to other relative heterocyclic analogs. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.017

文献信息

• [EN] ALPHAvBETA1 INTEGRIN ANTAGONISTS<br/>[FR] ANTAGONISTES DE L'INTÉGRINE ALPHAVBETA1
  申请人：UNIV SAINT LOUIS

  公开号：WO2020009889A1

  公开（公告）日：2020-01-09

  The present disclosure provides pharmaceutical agents, including those of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents are also provided. The compounds may be used for the inhibition or antagonism of integrins ανβ1 and/or α5β1. In some embodiments, the compounds provided herein exhibit reduced inhibitory or antagonistic activity of integrins ανβ3, ανβ5, ανβ6, ανβ8, and/or αIIbβ3.

  本公开提供药物制剂，包括公式(I)中的那些药物制剂；其中变量如本文所述定义。还提供了包含这种药物制剂的药物组合物、试剂盒和制造品。还提供了使用药物制剂的方法。这些化合物可用于抑制或拮抗整合素ανβ1和/或α5β1。在某些实施例中，本公开提供的化合物对整合素ανβ3、ανβ5、ανβ6、ανβ8和/或αIIbβ3的抑制或拮抗活性降低。
• [EN] THIAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES<br/>[FR] COMPOSES DE THIAZOLE EN TANT QUE DERIVES D'ANTAGONISTES DES RECEPTEURS DE L'INTEGRINE
  申请人：PHARMACIA CORP

  公开号：WO2004058760A1

  公开（公告）日：2004-07-15

  The present invention relates to pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the ανβ3 and/or the ανβ5 integrin without significantly inhibiting the ανβ6 integrin.

  本发明涉及包含式(I)化合物的药物组合物，以及选择性抑制或拮抗ανβ3和/或ανβ5整合素而不显著抑制ανβ6整合素的方法。
• Thiazole compounds as integrin receptor antagonists derivatives
  申请人：Wendt A. John

  公开号：US20050004189A1

  公开（公告）日：2005-01-06

  The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the α v β 3 and/or the α v β 5 integrin without significantly inhibiting the α v β 6 integrin.

  本发明涉及一类由式I表示或其药学上可接受的盐所表示的化合物，包括式I化合物的制药组合物，以及选择性抑制或拮抗αvβ3和/或αvβ5整合素而不显著抑制αvβ6整合素的方法。
• THIAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES
  申请人：Pharmacia Corporation

  公开号：EP1572690A1

  公开（公告）日：2005-09-14
• ALPHAvBETA1 INTEGRIN ANTAGONISTS
  申请人：Saint Louis University

  公开号：US20210284638A1

  公开（公告）日：2021-09-16

  The present disclosure provides pharmaceutical agents, including those of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents are also provided. The compounds may be used for the inhibition or antagonism of integrins ανβ 1 and/or α 5 β 1 . In some embodiments, the compounds provided herein exhibit reduced inhibitory or antagonistic activity of integrins ανβ 3 , ανβ 5 , ανβ 6 , ανβ 8 , and/or α IIb β 3 .